Skip to content
Anchorcite

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

William E. Klunk, Henry Engler, Agneta K. Nordberg, Yanming Wang, G. Blomqvist, Daniel P. Holt, Mats Bergström, Irina Savitcheva, Guofeng Huang, Sergio Estrada, Birgitta Ausén, Manik L. Debnath, Julien Barletta, Julie C. Price, Johan Sandell, Brian J. Lopresti, Anders E. Wall, Pernilla Koivisto, Gunnar Antoni, Chester A. Mathis, Bengt Långström

Annals of Neurology · 2004 · 4,546 citations

doi.org/10.1002/ana.20009

Abstract

This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94-fold, p = 0.0001). Large increases also were observed in parietal (1.71-fold, p = 0.0002), temporal (1.52-fold, p = 0.002), and occipital (1.54-fold, p = 0.002) cortex and the striatum (1.76-fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 +/- 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F-fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.

Cite this paper

Klunk, W. E., Engler, H., Nordberg, A. K., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., Ausén, B., Debnath, M. L., Barletta, J., Price, J. C., Sandell, J., Lopresti, B. J., Wall, A. E., Koivisto, P., Antoni, G., … Långström, B. (2004). Imaging brain amyloid in Alzheimer’s disease with pittsburgh Compound‐B. Annals of Neurology, 55(3), 306–319. https://doi.org/10.1002/ana.20009

Read it with every claim anchored

Add this paper to a project, ask questions of it, and get answers that point to the exact passage.

Start free

Related papers

  1. Clinical diagnosis of Alzheimer's disease1984
  2. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011
  3. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics2002
  4. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease2018
  5. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011

Metadata from OpenAlex (CC0). Citations are generated from the published record.